Surgical aortic valve replacement with a stented pericardial bioprosthesis: 5-year outcomes.
Aged
Animals
Aortic Valve
/ surgery
Aortic Valve Insufficiency
/ surgery
Aortic Valve Stenosis
/ surgery
Bioprosthesis
/ adverse effects
Cattle
Endocarditis
/ surgery
Female
Follow-Up Studies
Heart Valve Prosthesis
/ adverse effects
Heart Valve Prosthesis Implantation
/ adverse effects
Humans
Male
Middle Aged
Prosthesis Design
Thromboembolism
/ etiology
Treatment Outcome
Aortic valve disease
Bovine pericardial aortic bioprosthesis
Cardiac surgery
Surgical aortic valve replacement
Journal
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
ISSN: 1873-734X
Titre abrégé: Eur J Cardiothorac Surg
Pays: Germany
ID NLM: 8804069
Informations de publication
Date de publication:
03 08 2022
03 08 2022
Historique:
received:
06
01
2022
revised:
21
04
2022
accepted:
04
07
2022
pubmed:
6
7
2022
medline:
5
8
2022
entrez:
5
7
2022
Statut:
ppublish
Résumé
This analysis evaluated the safety, durability and haemodynamic performance of a stented bovine pericardial valve through 5 years of follow-up in patients with an indication for surgical aortic valve replacement. Kaplan-Meier analysis was used to estimate the incidence of survival and valve-related thromboembolism, major paravalvular leak, endocarditis, structural valve deterioration (SVD) and reintervention. The mean aortic gradient and New York Heart Association (NYHA) functional class were also evaluated. A total of 1118 patients have received the Avalus valve; 564 have completed the 5-year follow-up. The median follow-up was 4.85 years (4810 patient-years total follow-up). At baseline, the mean age was 70.2 ± 9.0 years; 75.1% of patients were male. The Society of Thoracic Surgeons predicted risk of mortality was 2.0 ± 1.4%. Most patients were in NYHA functional class II (46.8%) or III (40.3%). At the 5-year follow-up, the overall Kaplan-Meier survival rate was 88.1% (85.9-90.0%). The Kaplan-Meier event rates were 5.6% (4.3-7.2%) for thromboembolism, 4.4% (3.2-6.0%) for endocarditis, 0.2% (0.0-0.7%) for a major paravalvular leak and 3.2% (2.3-4.6%) for reintervention. There were no cases of SVD. The mean gradient decreased from 42.1 ± 17.1 mmHg at baseline, to 13.1 ± 4.7 mmHg at discharge and remained stable at 12.5 ± 4.6 mmHg at 5 years. More than 95% of patients were in NYHA functional class I/II 5 years after surgery. The findings of a high survival rate, excellent safety, no SVD and stable haemodynamic performance and functional status through 5 years of follow-up are encouraging. Additional follow-up is needed to assess the long-term durability of this contemporary surgical bioprosthesis.
Identifiants
pubmed: 35789382
pii: 6631229
doi: 10.1093/ejcts/ezac374
pmc: PMC9346377
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.
Références
Ann Thorac Surg. 2021 Apr;111(4):1198-1205
pubmed: 33011168
Ann Thorac Surg. 2019 May;107(5):1356-1362
pubmed: 30513317
Circulation. 1994 Jul;90(1):323-9
pubmed: 8026014
J Thorac Cardiovasc Surg. 2018 Oct;156(4):1368-1377.e5
pubmed: 29778342
N Engl J Med. 2019 May 2;380(18):1706-1715
pubmed: 30883053
Eur Heart J Cardiovasc Imaging. 2020 Oct 1;21(10):1116-1122
pubmed: 32243493
Eur J Cardiothorac Surg. 2017 Sep 01;52(3):425-431
pubmed: 28475690
Ann Thorac Surg. 2022 Jan 20;:
pubmed: 35065065
J Thorac Cardiovasc Surg. 2006 Nov;132(5):1137-43
pubmed: 17059935
Eur J Cardiothorac Surg. 2021 Jan 29;59(2):434-441
pubmed: 33141188
J Am Coll Cardiol. 2019 Feb 12;73(5):546-553
pubmed: 30732707
J Thorac Cardiovasc Surg. 2019 Nov 2;:
pubmed: 31864696
Circulation. 2019 Feb 1;:
pubmed: 30704298
Ann Thorac Surg. 2021 Nov;112(5):1424-1431
pubmed: 33338482
J Am Coll Cardiol. 2020 Nov 24;76(21):2492-2516
pubmed: 33213729
J Thorac Cardiovasc Surg. 2017 Mar;153(3):561-569.e2
pubmed: 27964975
J Thorac Cardiovasc Surg. 2020 Nov 12;:
pubmed: 33339597
J Thorac Cardiovasc Surg. 2020 Aug;160(2):371-381.e4
pubmed: 31590957
J Thorac Cardiovasc Surg. 2021 Aug 31;:
pubmed: 34538638
J Am Coll Cardiol. 2021 Jun 1;77(21):2717-2746
pubmed: 33888385
Ann Thorac Surg. 2001 Jan;71(1):92-9
pubmed: 11216817
Eur J Cardiothorac Surg. 2008 Apr;33(4):523-8
pubmed: 18313319
J Thorac Cardiovasc Surg. 2021 Jul 20;:
pubmed: 34364682
J Thorac Cardiovasc Surg. 2021 Nov;162(5):1478-1485
pubmed: 32340804
JACC Cardiovasc Interv. 2019 May 27;12(10):923-932
pubmed: 31122349
N Engl J Med. 2017 Apr 6;376(14):1321-1331
pubmed: 28304219